تحلیل اختیاری محصول
با اجازه شما، از تحلیلهای محدود و حریمخصوصیمحور استفاده میکنیم تا مسیرهای پژوهشی مؤثر را بشناسیم. از ردیاب تبلیغاتی یا بازپخش نشست استفاده نمیکنیم. این انتخاب را میتوانید در تنظیمات تغییر دهید. بخوانید سیاست حفظ حریم خصوصی.
Sanofi's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $104.3B | |
|---|---|---|
| Revenue (ttm) | 55.9B | |
| Net income (ttm) | 4.5B | |
| EPS (ttm) | $1.82 | |
| Shares out | 1.2B | |
| P/E (trailing) | 23.2x | |
| P/E (forward) | 8.4x | |
| Dividend | $2.42 (5.73%) | |
| Volume | 2,730,232 | |
| Beta | 0.28 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | Trend |
|---|---|---|---|---|---|
| Period | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $40.56B | $41.62B | $44.29B | $46.72B | +4.8% |
| Gross profit | $28.68B | $28.99B | $31.08B | $33.67B | +5.5% |
| Operating income | $10.40B | $6.89B | $7.40B | $6.80B | -13.2% |
| Net income | $8.37B | $5.40B | $5.56B | $7.81B | -2.3% |
| EPS (diluted) | $2.69 | $2.16 | $2.30 | $3.20 | +6.0% |
| EBITDA | $13.51B | $11.32B | $10.99B | $12.48B | -2.6% |
| R&D | $6.50B | $6.51B | $7.39B | $7.84B | +6.5% |
| SG&A | $8.74B | $9.48B | $9.82B | $10.24B | +5.4% |
Recent company headlines from major financial publishers.
Revenue accelerates beyond the historical 4.82% CAGR toward the 6.12% next-year estimate, driven by successful pipeline commercialization. Operating margins improve past 20%, and the equity partially re-rates toward the peer median.
Growth remains stable, anchored by vaccines and rare diseases. The 12.0x terminal multiple reflects a conservative partial re-rating from the current 8.4x, deliberately constrained below peers due to the rigid 97.7% dividend payout policy.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 6.3% | $61.9 | $69.2 | $78.4 | $89.5 | $89.5 |
| 7.3% | $51.2 | $56.0 | $61.9 | $69.2 | $78.4 |
| 8.3% | $43.6 | $47.1 | $51.2 | $56.0 | $61.9 |
| 9.3% | $38.0 | $40.6 | $43.6 | $47.1 | $51.2 |
| 10.3% | $33.6 | $35.7 | $38.0 | $40.6 | $43.6 |
Upcoming earnings date and setup when available.
رتبهای که نسخهٔ پژوهشی منتشرشدهٔ هر ماه داشت. رتبه قیمت در تاریخ تحلیل را با ارزش منصفانه مقایسه میکند و سابقهای از درستی یا نادرستی ارزیابی نیست.
| سال | دی | بهمن | اسفند | فروردین | اردیبهشت | خرداد | تیر | مرداد | شهریور | مهر | آبان | آذر |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
